Abstracts

ENDING THE HIV EPIDEMIC IN BALTIMORE: A MODELING STUDY

Last year, the US government announced a plan to reduce HIV incidence by 90% by 2030 through the “90-90-90” target. However, it is not clear how these targets will perform in local epidemics, such as the one in Baltimore City, driven by heterogeneities in HIV transmission and access to care.  We extended the Johns Hopkins…

F/TAF VS F/TDF FOR PrEP: HOW MUCH IS “BETTER” WORTH?

F/TAF is approved as a safer, non-inferior PrEP option compared with F/TDF. With generic F/TDF expected in 2020, we examine how much more payers should be willing to pay for the improved safety profile of branded F/TAF. We assembled safety data for F/TAF and F/TDF in an age-stratified population of 123,610 US MSM without HIV…

HIGHER INCOME INEQUALITY IS ASSOCIATED WITH LOWER CUMULATIVE ANTIRETROVIRAL ADHERENCE

Tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) is associated with viral suppression and predicts future viremia. However, its association with the social determinants of health (SDoH) in people living with HIV (PLWH) has not been evaluated. DBS for TFV-DP were prospectively collected from a clinical cohort of PLWH receiving tenofovir disoproxil fumarate (TDF)-based therapy…

USE CASE FOR NEAR POINT OF CARE HIV VIRAL LOAD: TARGETED TESTING AT LARGE FACILITIES

Point-of-care (POC) technologies in resource-limited settings can circumvent challenges of centralized laboratory testing, leading to an increased proportion of results used for clinical management. However, higher device costs and uncertain use cases for POC in routine care have inhibited scale-up. To address this gap, we investigated the feasibility and cost of targeted near-POC viral load…